Uncategorized

Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy

Pick the Right Patent—or Leave Billions on the Table: The “One Patent Per Product” Rule and the PTE Playbook
In pharma, the difference between a breakthrough and a blockbuster can come down to a single decision made years earlier—often before the marke…

Pick the Right Patent Or Leave Billions on the Table: The Definitive Guide to the One-Patent-Per-Product Rule and PTE Selection Strategy Read Post »

Uncategorized

Win More 505(b)(2) Business: A guide for CDMOs and specialty labs targeting companies developing 505(b)(2) follow-on drugs

The 505(b)(2) playbook is getting crowded. Here’s how CDMOs and specialty labs can still win.
If you’re a CDMO or specialty lab serving the 505(b)(2) market, you’ve probably felt it: more competitors, tighter timelines, and customers asking for “faster…

Win More 505(b)(2) Business: A guide for CDMOs and specialty labs targeting companies developing 505(b)(2) follow-on drugs Read Post »

Uncategorized

India’s Drug Patent Clock: The Definitive Guide to How Long Drug Patent Protection Actually Lasts in India

India’s “drug patent clock” isn’t a clock at all—it’s a maze. Here’s what actually determines how long exclusivity lasts.
If you’ve ever heard that a drug patent in India “lasts 20 years,” you’ve heard only the headline—not the story.
In practice, the …

India’s Drug Patent Clock: The Definitive Guide to How Long Drug Patent Protection Actually Lasts in India Read Post »

Biotechblog
Scroll to Top